Sonnet BioTherapeutics Holdings (SONN) Stock Statistics & Valuation Metrics

Sonnet BioTherapeutics Holdings has a market cap or net worth of $28.69M. The enterprise value is $28.96M.

Sonnet BioTherapeutics Holdings has 3,332,728 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sonnet BioTherapeutics Holdings’s return on equity (ROE) is 15.31 and return on invested capital (ROIC) is 3339.05%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Sonnet BioTherapeutics Holdings had revenue of 18.63K and earned -7.44M in profits. Earnings per share was -11.35.

In the last 12 months, operating cash flow was -11.62M and capital expenditures -12.00K, giving a free cash flow of -11.63M billion.

Sonnet BioTherapeutics Holdings pays an annual dividend of ―, resulting in a dividend yield of ―

Sonnet BioTherapeutics Holdings upcoming earnings date is ―, ―.

Sonnet BioTherapeutics Holdings as a current ratio of 0.66, with Debt / Equity ratio of 13.66%

In the past 12 months, Sonnet BioTherapeutics Holdings has paid 0.00 in taxes.

Sonnet BioTherapeutics Holdings EV to EBITDA ratio is -0.37, with an EV/FCF ratio of -0.51.

Sonnet BioTherapeutics Holdings has $2.06M in cash and marketable securities with $90.45K in debt, giving a net cash position of -$1.97M billion.

Gross margin is -343.40%, with operating margin of -63617.91%, and net profit margin of -39929.30%.

The average price target for Sonnet BioTherapeutics Holdings is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold